I think generic companies are businesses. They look at developing products, typically as patents expire. They have a timeframe for that, and with this bill, you'd be looking at developing a product or a developing country market, not a Canadian market, not a U.S. market, not a European market, at an earlier point.
What I'm saying is they would need to develop the product as Apotex did, to do the testing, to get approval from Health Canada, and as the speaker from South Africa has said a couple of times, the system is all backwards. They have to do that before they can go to a country and indicate they have the capacity to provide the product. So for a developing country to come to Canada or Apotex or Teva or anyone and say they'd like them to bid on a particular product, that is a very backward process, as I said. They don't have the right to do that. They would have to start that process. It's going to take some time to develop the product, to get approval, let alone to negotiate the licence with the brand company.
So I think it's very important that the companies have a clear right under this legislation, if it's going to be effective, to make a product that will get a licence, and if they follow the rules on where it's shipped, etc., and diversion, that they can continue to make the product. Then we'll have a much greater chance of having products made under our legislation.